2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
A pre–new drug application meeting was held with representatives from Turning Point Therapeutics, Inc. and the FDA to discuss repotrectinib as a potential therapeutic option for patients with ROS1-positive advanced non–small cell lung cancer.
A pre–new drug application (NDA) meeting was held with representatives from Turning Point Therapeutics, Inc. and the FDA to discuss repotrectinib as a potential therapeutic option for patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).1
The clinical-stage precision oncology company shared that they received positive feedback from the regulatory agency regarding the planned patient follow-up within the ROS1-positive, advanced NSCLC cohorts of the ongoing phase 1/2 TRIDENT trial (NCT03093116). Specifically, at the time of the application submission, the company will share findings from those with ROS1-positive disease who are TKI-naïve and TKI-pretreated and who have at least 6 months of follow-up from the time of their first post-baseline scan.
“We continue to be encouraged by our collaborative meetings with the FDA,” Mohammad Hirmand, MD, chief medical officer of Turning Point Therapeutics, Inc., stated in a press release. “The planned NDA submission represents an important milestone for our company. The unmet need in ROS1-positive advanced NSCLC patients is significant, and we continue to believe that repotrectinib could offer a best-in-class profile for the treatment of these patients.”
Repotrectinib is a next-generation ROS1 and TRK TKI that was granted a breakthrough therapy designation from the FDA in May 2022.2 The designation was supported by pooled efficacy findings from approximately 50 patients who were enrolled to either phase of the TRIDENT-1 trial, which was comprised of 6 expansion cohorts.
Patients with ROS1-positive NSCLC who were naïve to ROS1 TKIs, received 2 prior ROS1 TKIs, or 1 prior ROS1 TKI comprised expansion cohorts 1, 2, and 3, respectively. Those with NTRK-positive solid tumors who were naïve to TRK TKIs or who previously received TRK TKIs were included in expansion cohorts 5 and 6, respectively.
The primary end point in each cohort for the phase 2 portion of the research is objective response rate (ORR). Secondary end points include duration of response (DOR), clinical benefit rate, progression-free survival (PFS), overall survival, and intracranial ORR.
Dose-limiting toxicities were evaluated in the phase 1 portion of the trial. Investigators established 160 once daily for 14 days followed by 160 twice daily if tolerated as the recommended phase 2 dose of repotrectinib in TKI-naïve and -refractory patients who had advanced ALK/ROS1/NTRK-positive solid tumors.3
Interim data from expansion cohort 4 showed that in patients with NSCLC and ROS1 positivity who previously received 1 TKI without chemotherapy, repotrectinib elicited an ORR of 67% (95% CI, 22%-96%); notably, 4 of the 5 patients who received treatment achieved a complete response (CR).4 The DOR to treatment ranged from 1.0+ months to 5.7+ months. Moreover, all patients who experienced a CR continued to respond at the time of data cutoff.
Repotrectinib was also noted to have favorable tolerability, according to pooled safety findings from both phases of the trial spanning cohorts (n = 185).5 Most of the treatment-related adverse effects experienced with the agent were grade 1 or 2.
Seventy-nine percent of treatment-emergent adverse effects (TEAEs) were grade 1 in severity. Low-grade dizziness was the most common TEAE experienced by those who received repotrectinib, and it occurred in 58.4% of patients.
Moreover, 17.8% of patients required dose reductions, and 8.6% discontinued treatment due to toxicities.